KR102885856B1 - 효능 검정 - Google Patents

효능 검정

Info

Publication number
KR102885856B1
KR102885856B1 KR1020237032315A KR20237032315A KR102885856B1 KR 102885856 B1 KR102885856 B1 KR 102885856B1 KR 1020237032315 A KR1020237032315 A KR 1020237032315A KR 20237032315 A KR20237032315 A KR 20237032315A KR 102885856 B1 KR102885856 B1 KR 102885856B1
Authority
KR
South Korea
Prior art keywords
cells
tgfβ1
culture medium
mpc
mesenchymal lineage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237032315A
Other languages
English (en)
Korean (ko)
Other versions
KR20230140604A (ko
Inventor
폴 시몬스
콜비 수이레
피오나 씨
Original Assignee
메조블라스트 인터내셔널 에스에이알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901605A external-priority patent/AU2015901605A0/en
Application filed by 메조블라스트 인터내셔널 에스에이알엘 filed Critical 메조블라스트 인터내셔널 에스에이알엘
Publication of KR20230140604A publication Critical patent/KR20230140604A/ko
Application granted granted Critical
Publication of KR102885856B1 publication Critical patent/KR102885856B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
KR1020237032315A 2015-05-05 2016-05-04 효능 검정 Active KR102885856B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2015901605 2015-05-05
AU2015901605A AU2015901605A0 (en) 2015-05-05 Potency assay
KR1020177034098A KR102582602B1 (ko) 2015-05-05 2016-05-04 효능 검정
PCT/EP2016/060049 WO2016177805A1 (en) 2015-05-05 2016-05-04 Potency assay

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177034098A Division KR102582602B1 (ko) 2015-05-05 2016-05-04 효능 검정

Publications (2)

Publication Number Publication Date
KR20230140604A KR20230140604A (ko) 2023-10-06
KR102885856B1 true KR102885856B1 (ko) 2025-11-14

Family

ID=56087237

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237032315A Active KR102885856B1 (ko) 2015-05-05 2016-05-04 효능 검정
KR1020177034098A Active KR102582602B1 (ko) 2015-05-05 2016-05-04 효능 검정

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177034098A Active KR102582602B1 (ko) 2015-05-05 2016-05-04 효능 검정

Country Status (9)

Country Link
US (3) US11795435B2 (cg-RX-API-DMAC7.html)
EP (2) EP3292199B1 (cg-RX-API-DMAC7.html)
JP (4) JP6797833B2 (cg-RX-API-DMAC7.html)
KR (2) KR102885856B1 (cg-RX-API-DMAC7.html)
CN (2) CN107771220B (cg-RX-API-DMAC7.html)
AU (3) AU2016258980B2 (cg-RX-API-DMAC7.html)
CA (1) CA2984987C (cg-RX-API-DMAC7.html)
ES (2) ES2911266T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016177805A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
US11930808B2 (en) * 2018-09-20 2024-03-19 Universidad De Valladolid Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions and comprising the same
EP4772245A3 (en) * 2019-01-02 2026-08-19 Mesoblast International Sàrl Method for treating lower back pain
US12702683B2 (en) 2019-01-03 2026-08-11 Mesoblast International Sárl Method for improving visual acuity
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
CA3180808A1 (en) * 2020-04-20 2021-10-28 Longeveron Inc. Potency assay
US20260209709A1 (en) * 2022-12-23 2026-07-23 Kangstem Biotech Co., Ltd. Method for selecting stem cells with enhanced cartilage differentiation capability and cell therapy product comprising same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011196840A (ja) 2010-03-19 2011-10-06 Univ Of Tokyo 急性大動脈解離の検査方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089815A (en) 1951-10-11 1963-05-14 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
KR960702518A (ko) 1993-05-17 1996-04-27 린다 에스, 스티븐슨 Hiv 감염 및 aids에 대한 리보자임 유전자 치료(ribozyme gene therapy for hiv infection and aids)
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
US6566051B1 (en) 1999-01-15 2003-05-20 Medtox Scientific, Inc. Lateral flow test strip
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AU7362301A (en) 2000-06-22 2002-01-02 Sam L Austin Bioadhesive compositions and methods of preparation and use
JP4264348B2 (ja) 2001-08-20 2009-05-13 プロテオム システムズ リミテッド 診断検査方法および装置
WO2004046729A2 (en) 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
US8367405B2 (en) 2005-04-12 2013-02-05 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
KR100802011B1 (ko) * 2005-08-10 2008-02-12 인하대학교 산학협력단 층분리배양법을 이용한 골수에서의 중간엽 줄기세포분리방법
JP2014530065A (ja) * 2011-10-11 2014-11-17 ボーン セラピューティクスソシエテ アノニム 増殖分化因子８（ｇｄｆ‐８）の使用
SG11201509430WA (en) * 2013-05-16 2015-12-30 Agency Science Tech & Res Heparan sulphates
KR20150016117A (ko) * 2013-07-30 2015-02-11 코아스템(주) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물
CN103990181B (zh) * 2014-05-26 2015-07-08 中国人民解放军第四军医大学 一种具有诱导活性微载体-细胞复合物的制备方法及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011196840A (ja) 2010-03-19 2011-10-06 Univ Of Tokyo 急性大動脈解離の検査方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C.Cao et al., The Spine Journal, Vol. 15, 2015, pp. 530-538.*
Kyurkchive et al., World Journal of Stem Cells, Vol. 6, No. 5, 2014, pp. 552-570.
L.Wen et al., PLOS ONE, Vol. 9, No. 7, 2014.

Also Published As

Publication number Publication date
AU2022203140A1 (en) 2022-06-02
JP2018517900A (ja) 2018-07-05
CN107771220A (zh) 2018-03-06
KR20230140604A (ko) 2023-10-06
AU2025205043A1 (en) 2025-07-24
US20240409898A1 (en) 2024-12-12
EP4015624B1 (en) 2025-02-19
CA2984987A1 (en) 2016-11-10
JP7335222B2 (ja) 2023-08-29
JP2023159260A (ja) 2023-10-31
ES3018944T3 (en) 2025-05-19
CA2984987C (en) 2023-10-10
AU2016258980A1 (en) 2017-11-23
JP2021036892A (ja) 2021-03-11
BR112017023660A2 (pt) 2018-07-17
HK1247236A1 (zh) 2018-09-21
CN107771220B (zh) 2022-07-05
CN115141872A (zh) 2022-10-04
JP6797833B2 (ja) 2020-12-09
WO2016177805A1 (en) 2016-11-10
EP4015624A1 (en) 2022-06-22
JP2026012704A (ja) 2026-01-27
US20240076621A1 (en) 2024-03-07
KR102582602B1 (ko) 2023-09-25
JP7754893B2 (ja) 2025-10-15
KR20180041621A (ko) 2018-04-24
AU2016258980B2 (en) 2022-02-17
US20200140822A1 (en) 2020-05-07
ES2911266T3 (es) 2022-05-18
EP3292199A1 (en) 2018-03-14
US11795435B2 (en) 2023-10-24
EP3292199B1 (en) 2022-01-12
AU2022203140B2 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
AU2022203140B2 (en) Potency assay
AU2020204805B2 (en) Method for treating lower back pain
Sesia et al. Anti‐Inflammatory/tissue repair macrophages enhance the cartilage‐forming capacity of human bone marrow‐derived mesenchymal stromal cells
Brady et al. Synergy between myogenic and non‐myogenic cells in a 3D tissue‐engineered craniofacial skeletal muscle construct
Komabashiri et al. Efficacy of chitinase-3-like protein 1 as an in vivo bone formation predictable marker of maxillary/mandibular bone marrow stromal cells
HK1247236B (en) Potency assay
BR112017023660B1 (pt) Método para selecionar células precursoras de linhagem mesenquimal ou células-tronco humanas, composições e uso das mesmas
Hofer Traumatized muscle-derived multipotent progenitor cells: Pro-angiogenic activity, promotion of nerve growth, and osteogenic differentiation
Beaumont Dental pulp stem cells and leukocyte-and platelet-rich fibrin as candidate therapies for articular cartilage and tendon repair
O’Sullivan Glycosaminoglycan Dependent Isolation of Mesenchymal Chondroprogenitor Populations from Human Bone Marrow

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)